Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

VYNE Therapeutics Q4 Adjusted EPS $(0.18) Beats $(0.50) Estimate, Sales $76.00K Miss $150.00K Estimate

Author: Benzinga Newsdesk | February 29, 2024 09:12am
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.50) by 64 percent. This is a 93.94 percent increase over losses of $(2.97) per share from the same period last year. The company reported quarterly sales of $76.00 thousand which missed the analyst consensus estimate of $150.00 thousand by 49.33 percent. This is a 1.17K percent increase over sales of $6.00 thousand the same period last year.

Posted In: VYNE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist